EVALUATION OF TREATMENT OUTCOMES WITH LEVETIRACETAM IN PATIENTS WITH EPILEPSY
Main Article Content
Abstract
Background: Epilepsy is a common chronic neurological disorder that significantly affects patients’ health and quality of life. Levetiracetam is a newer-generation antiepileptic drug that has demonstrated good seizure control efficacy and a favorable safety profile. However, in Vietnam, data evaluating the therapeutic effectiveness of levetiracetam in adult patients with epilepsy remain limited. Objective: To evaluate the treatment outcomes of levetiracetam in hospitalized patients with epilepsy at Can Tho Central General Hospital. Materials and Methods: A cross-sectional descriptive study was conducted on 65 patients aged ≥16 years diagnosed with epilepsy. Seizure control, recurrence, and adverse effects were assessed during the most recent 3-month treatment period. Results: The study was conducted on 65 patients with epilepsy aged 16 years or older. After 3 months of treatment with levetiracetam, 81.5% of patients achieved good seizure control. The seizure recurrence rate was 27.7%, with no recurrence recorded during the first month. Adverse effects occurred in 40.0% of patients, mainly involving psychiatric–behavioral and neurological manifestations; most were mild, transient, and did not require treatment discontinuation. Conclusion: Levetiracetam demonstrated high efficacy in seizure control and good tolerability among the patients with epilepsy included in this study. It is an effective and safe treatment option for patients with epilepsy.
Keywords
Levetiracetam, epilepsy, seizure control, recurrence, adverse effects
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. World Health Organization. Epilepsy: a public health imperative. Geneva: World Health Organization. 2019. Available from: https://www.who.int/publications/i/item/epilepsy-a- public-health-imperative.
3. Zhu L., Wu X., Zhu J., Fan H. Efficacy and safety of levetiracetam versus carbamazepine in the treatment of newly diagnosed focal epilepsy: a meta-analysis. Medicine. 2022. 101(36), e30485, doi:10.1097/MD.0000000000030485.
4. Biện Thị Trúc Hà, Nguyễn Văn Khoe. Đặc điểm lâm sàng và đánh giá kết quả điều trị bệnh nhân động kinh bằng levetiracetam tại Bệnh viện Đa khoa tỉnh Trà Vinh. Tạp chí Y học Việt Nam. 2022. 512(2), doi:10.51298/vmj.v512i2.2296.
5. Howard P., Remi J., Remi C., Charlesworth S. Levetiracetam. Journal of Pain and Symptom Management. 2018. 56(4), 645–649, doi:10.1016/j.jpainsymman.2018.07.012.
6. Hophing L., Kyriakopoulos P., Bui E. Sex and gender differences in epilepsy. International Review of Neurobiology. 2022. 164, 235–276, doi:10.1016/bs.irn.2022.06.012.
7. Angurana S.K., Suthar R. Efficacy and safety of levetiracetam versus phenytoin as second-line antiseizure medication for pediatric convulsive status epilepticus: a systematic review and metaanalysis of randomized controlled trials. Journal of Tropical Pediatrics. 2021. 67(2), doi:10.1093/tropej/fmab014.
8. Fang J., Huang C., Zhang H., Wang J., Lin J., et al. Levetiracetam for seizure prophylaxis in neurocritical care: a systematic review and meta-analysis. Neurocritical Care. 2022. 36(1), 248– 258, doi:10.1007/s12028-021-01296-z.
9. U.S. Food and Drug Administration. KEPPRA® (levetiracetam) Prescribing Information. Silver Spring (MD): U.S. Food and Drug Administration. Revised March 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021035s115,021505s053lbl.pdf.
10. Bùi Thị Liên, Lê Thị Bình, Đoàn Mai Phương, Võ Hồng Khôi. Đặc điểm lâm sàng và chất lượng cuộc sống của người bệnh động kinh tại Trung tâm Thần kinh, Bệnh viện Bạch Mai năm 2020– 2021. Tạp chí Y học Việt Nam. 2022. 510(1), doi:10.51298/vmj.v510i1.1897.